These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1172 related articles for article (PubMed ID: 20137358)
21. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases. Miettinen M; Sobin LH; Lasota J Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146 [TBL] [Abstract][Full Text] [Related]
22. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774 [TBL] [Abstract][Full Text] [Related]
23. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Rutkowski P; Nowecki ZI; Michej W; Debiec-Rychter M; Woźniak A; Limon J; Siedlecki J; Grzesiakowska U; Kakol M; Osuch C; Polkowski M; Głuszek S; Zurawski Z; Ruka W Ann Surg Oncol; 2007 Jul; 14(7):2018-27. PubMed ID: 17473953 [TBL] [Abstract][Full Text] [Related]
24. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. Lee HE; Kim MA; Lee HS; Lee BL; Kim WH J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383 [TBL] [Abstract][Full Text] [Related]
25. Prognosis of gastrointestinal stromal tumors. Bertin M; Angriman I; Scarpa M; Mencarelli R; Ranzato R; Ruffolo C; Polese L; Iacobone M; D'Amico DF Hepatogastroenterology; 2007; 54(73):124-8. PubMed ID: 17419245 [TBL] [Abstract][Full Text] [Related]
26. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234 [TBL] [Abstract][Full Text] [Related]
27. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM; J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486 [TBL] [Abstract][Full Text] [Related]
28. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate]. Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732 [TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumors treatment in the Imatinib era. The role of fair indication. Vendettuoli M; Pironi D; Pontone S; Panarese A; La Gioia G; Arcieri S; Romani AM; Palazzini G; Filippini A Minerva Chir; 2012 Apr; 67(2):165-73. PubMed ID: 22487918 [TBL] [Abstract][Full Text] [Related]
31. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Hassan I; You YN; Dozois EJ; Shayyan R; Smyrk TC; Okuno SH; Donohue JH Dis Colon Rectum; 2006 May; 49(5):609-15. PubMed ID: 16552495 [TBL] [Abstract][Full Text] [Related]
32. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Goh BK; Chow PK; Yap WM; Kesavan SM; Song IC; Paul PG; Ooi BS; Chung YF; Wong WK Ann Surg Oncol; 2008 Aug; 15(8):2153-63. PubMed ID: 18546045 [TBL] [Abstract][Full Text] [Related]
34. Gastric GISTs. Personal experience. Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602 [TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal stromal tumors (GIST) related emergencies. Sorour MA; Kassem MI; Ghazal Ael-H; El-Riwini MT; Abu Nasr A Int J Surg; 2014; 12(4):269-80. PubMed ID: 24530605 [TBL] [Abstract][Full Text] [Related]
36. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676 [TBL] [Abstract][Full Text] [Related]
38. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826 [TBL] [Abstract][Full Text] [Related]
39. Prevalence and management of gastrointestinal stromal tumors. Machado-Aranda D; Malamet M; Chang YJ; Jacobs MJ; Ferguson L; Silapaswan S; Goriel Y; Kolachalam R; Mittal VK Am Surg; 2009 Jan; 75(1):55-60. PubMed ID: 19213398 [TBL] [Abstract][Full Text] [Related]
40. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]